{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:45:02Z","timestamp":1792118702334,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Next-generation sequencing (NGS) is an advanced sequencing technology that enables rapid sequencing of numerous DNA strands and performs simultaneous analysis of various genes and diverse genomic characteristics. While there is a lack of substantial evidence available, the extent to which NGS may improve clinical outcomes among cancer patients in a real-world scenario remains uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the clinical utility of NGS in patients treated with advanced non-small cell lung cancer (NSCLC) and its impact on real-world clinical outcomes, treated with targetable or non-targetable agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>This was a prospective observational study conducted in 322 participants distributed over 2 broad categories- NGS and non-NGS. The NGS category consisted of patients who underwent genetic mutation screening by the NGS method. This group was further categorized into 2 subgroups-NGS\u2014targetable and NGS-non-targetable. The non-NGS category consisted of patients who did not undergo mutation testing by the NGS method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was a significant difference in overall survival between NGS and non-NGS groups (P\u2005=\u2005.0038). There was a significant difference between NGS targetable and non-targetable groups in terms of progression-free survival (PFS; P\u2005=\u2005.0016) and overall survival (OS; P\u2005&amp;lt;\u2005.0001). There was a significant difference between NGS-matched and non-matched groups in terms of PFS (P\u2005&amp;lt;\u2005.00011) as well as OS (P\u2005&amp;lt;\u2005.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>NGS significantly improved survival in advanced NSCLC. Patients who received treatments matched to their NGS results experienced significantly longer survival compared to those with non-matched treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf168","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T21:46:24Z","timestamp":1751319984000},"source":"Crossref","is-referenced-by-count":1,"title":["Utility and real-world clinical outcomes of next-generation sequencing in advanced non-small-cell lung cancer in the South Indian population"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-5253","authenticated-orcid":false,"given":"Thattungal Manoharan","family":"Anoop","sequence":"first","affiliation":[{"name":"Additional Professor, Department of Medical Oncology, Regional Cancer Centre , Thiruvananthapuram ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Raj","sequence":"additional","affiliation":[{"name":"Senior Resident, Department of Medical Oncology, Regional Cancer Centre , Thiruvananthapuram ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Nair","sequence":"additional","affiliation":[{"name":"Assistant Professor, Department of Medical Oncology, Regional Cancer Centre , Thiruvananthapuram ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athira","family":"Vincent","sequence":"additional","affiliation":[{"name":"DM Resident, Department of Medical Oncology, Regional Cancer Centre , Thiruvananthapuram ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"2025073107414696000_CIT0001","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5152\/balkanmedj.2021.20086","article-title":"Comparison of PD-L1, EGFR, ALK, and ROS1 status between surgical samples and cytological samples in non-small cell lung carcinoma","volume":"38","author":"Ekin","year":"2021","journal-title":"Balkan Med J"},{"key":"2025073107414696000_CIT0002","doi-asserted-by":"publisher","first-page":"102200","DOI":"10.1016\/j.esmoop.2023.102200","article-title":"Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study","volume":"9","author":"Kang","year":"2024","journal-title":"ESMO Open"},{"key":"2025073107414696000_CIT0003","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"2025073107414696000_CIT0004","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.21037\/tlcr-23-118","article-title":"The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors","volume":"12","author":"Luna","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2025073107414696000_CIT0005","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.hoc.2016.08.012","article-title":"Diagnosis and treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"31","author":"Arbour","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"2025073107414696000_CIT0006","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/curroncol29020057","article-title":"ROS-1 fusions in non-small-cell lung cancer: evidence to date","volume":"29","author":"Gendarme","year":"2022","journal-title":"Current Oncol"},{"key":"2025073107414696000_CIT0007","doi-asserted-by":"publisher","first-page":"152797","DOI":"10.1016\/j.prp.2019.152797","article-title":"Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1","volume":"216","author":"Liu","year":"2020","journal-title":"Pathol Res Pract"},{"key":"2025073107414696000_CIT0008","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1146\/annurev-med-051718-013524","article-title":"Precision management of advanced non-small cell lung cancer","volume":"71","author":"Yang","year":"2020","journal-title":"Annu Rev Med"},{"key":"2025073107414696000_CIT0009","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/path.5344","article-title":"Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer","volume":"250","author":"Alborelli","year":"2020","journal-title":"J Pathol"},{"issue":"1","key":"2025073107414696000_CIT0010","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-024-01839-8","article-title":"Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine","volume":"22","author":"Dupain","year":"2024","journal-title":"BMC Biology"},{"key":"2025073107414696000_CIT0011","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.currproblcancer.2020.100562","article-title":"Next generation sequencing in lung cancer: an initial experience from India","volume":"44","author":"Gupta","year":"2020","journal-title":"Curr Probl Cancer"},{"key":"2025073107414696000_CIT0012","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/j.cllc.2025.02.001","article-title":"Genomic profiling of driver gene alterations in patients with non-small cell lung cancer, patterns of treatment and impact on survival outcomes: a single center experience of more than 1200 patients","volume":"26","author":"Shah","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"2025073107414696000_CIT0013","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1016\/j.cllc.2024.07.011","article-title":"Landscape of clinically relevant genomic alterations in the Indian non-small cell lung cancer patients","volume":"25","author":"Jha","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"2025073107414696000_CIT0014","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2018.9824","article-title":"Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting","volume":"320","author":"Presley","year":"2018","journal-title":"JAMA"},{"key":"2025073107414696000_CIT0015","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","article-title":"PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma","volume":"89","author":"Cooper","year":"2015","journal-title":"Lung Cancer"},{"key":"2025073107414696000_CIT0016","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1016\/j.ejca.2015.08.013","article-title":"Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas","volume":"51","author":"Kim","year":"2015","journal-title":"European J Cancer"},{"key":"2025073107414696000_CIT0017","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/ijms20040824","article-title":"Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers","volume":"20","author":"Pawelczyk","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025073107414696000_CIT0018","doi-asserted-by":"publisher","first-page":"157","DOI":"10.20892\/j.issn.2095-3941.2016.0009","article-title":"Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and\/or prognostic in non-small cell lung cancer","volume":"13","author":"Mino-Kenudson","year":"2016","journal-title":"Cancer Biol Med"},{"key":"2025073107414696000_CIT0019","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.18632\/oncotarget.3097","article-title":"B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer","volume":"6","author":"Mao","year":"2015","journal-title":"Oncotarget"},{"key":"2025073107414696000_CIT0020","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","article-title":"Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer","volume":"25","author":"Azuma","year":"2014","journal-title":"Ann Oncol"},{"key":"2025073107414696000_CIT0021","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2147\/CMAR.S436808","article-title":"The prognosis of advanced non-small cell lung cancer patients with precision-targeted therapy guided by NGS testing or routine testing","volume":"15","author":"Tu","year":"2023","journal-title":"Cancer Manag Res"},{"key":"2025073107414696000_CIT0022","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"2025073107414696000_CIT0023","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/medicina60020236","article-title":"Next-generation sequencing in lung cancers-a single-center experience in Taiwan","volume":"60","author":"Lai","year":"2024","journal-title":"Medicina"},{"key":"2025073107414696000_CIT0024","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-14-0603","article-title":"Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses","volume":"20","author":"Tsimberidou","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025073107414696000_CIT0025","doi-asserted-by":"publisher","first-page":"e1996","DOI":"10.1634\/theoncologist.2020-0148","article-title":"Clinical impact of plasma and tissue next-generation sequencing in advanced non-small cell lung cancer: a real-world experience","volume":"25","author":"Bonanno","year":"2020","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf168\/63630165\/oyaf168.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf168\/63630165\/oyaf168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf168\/63630165\/oyaf168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T11:41:53Z","timestamp":1753962113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf168\/8178845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf168","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf168"}}